COMP <GO>
AVTR vs BIO // ENTERPRISE SCALE & MARKET CAP
Avantor Inc. (NYSE) VS. Bio-Rad Laboratories Inc. (NYSE) • 15-METRIC TALLY: AVTR 2
— BIO 10
▲ ENTERPRISE SCALE & MARKET CAP LEADER: AVTR
LAST: $16.05 (-3.78%) • MKT CAP: $10.88B
market-cap
$10.88B
LAST: $372.18 (-3.18%) • MKT CAP: $9.95B
market-cap
$9.95B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVTR VS. BIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVTR | BIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 32.70% | 51.90% | -19.20 | BIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.10% | 0.50% | -2.60 | BIO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 60.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.38% | 3.64% | +0.74 | AVTR | /fcf-yield <GO> |
| Operating Margin | -3.80% | 1.80% | -5.60 | BIO | /operating-margins <GO> |
| Net Profit Margin | -8.10% | 29.40% | -37.50 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | -3.40% | 0.70% | -4.10 | BIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.88 | 3.59 | -1.71 | BIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | BIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 50.1 | -1.80 | BIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.04 | -0.03 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 12.6x | +18.40 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $10.88B | $9.95B | $924.3M | AVTR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVTR REV | BIO REV | AVTR GROSS % | BIO GROSS % | AVTR FCF | BIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.55B | $2.58B | 32.7% | 51.9% | $495.0M | $374.6M |
| FY 2024 | $6.78B | $2.57B | 33.6% | 53.7% | $692.0M | $289.6M |
| FY 2023 | $6.97B | $2.67B | — | — | $556.5M | $254.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVTR // BETA 1.01
BIO // BETA 1.04